Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut

ALLURION TECHNOLOGIES, INC.

Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.
Q4 operating loss $17.1M vs $25.7M YoY, includes $4.6M restructuring and financing costs.
Q4 gross margin 45% vs 78% YoY; full-year 67%; expects margin expansion in 2025.
Sales resumed in France Feb 12, 2025; positive AUDACITY FDA trial readout; next-gen balloon launched.
Cash $15.4M at Dec 31, 2024; recent financings expected to fund through potential FDA approval in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.